Cancer

February 10, 2019

Combinatorial therapy for Metastatic human tumors:  A pharmaceutical mixture encompassing metformin and Navitoclax/ABT-263 (MAN)  decreases the expression of c-Src protein, inhibits the expression of a number of enzymes in glycolytic cycle, and suppresses proliferation, migration, invasion, tumorigenesis and metastasis via upregulation of its target gene, 11/February/2017, 12.34 am

Introduction: What they say: A study from the State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen […]
February 10, 2019

Combinatorial therapy for Acute Myeloid Leukemia:  A pharmaceutical mixture encompassing Metformin and Navitoclax/ABT-263 (MAN) decreases the expression of BCLAF1,  promotes differentiation of acute myeloid leukaemia cells, restores treatment responsiveness, increases therapeutic index of anticancer drugs, and promotes regression of AML via up-regulation of its target gene, 10/February/2019, 11.27 pm

Introduction: What they say: A study from the Institute of Genetics and Biophysics, CNR, Naples, Italy; and Department of Biochemistry, Biophysics and General Pathology, Second University […]
February 9, 2019

Combinatorial therapy for metastatic prostate cancer: A therapeutic mix encompassing Metformin and Navitoclax/ABT-263 (MAN) inhibits the expression of CDC42, CDC42EP3, RAC1 and ARPC5, and GAS6, suppresses the expression of stem cell molecules CD44 and EZH2, promotes epithelial phenotype, suppresses tumorigenesis, migration, invasion, stem cell regeneration and metastasis via upregulation of its target gene, 9/February/2018, 6.53 am

Introduction: What they say: A study from the Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Science Park, Texas 78957, USA […]
February 6, 2019

Combinatorial therapy for targeting cancer stem cells in Myeloid leukaemia (ML): a pharmaceutical mixture encompassing Metformin and Navitoclax/ABT-263  inhibits cytosolic aminotransferase BCAT1 expression, increases a-ketoglutarate levels, promotes degradation of HIF1a levels, increases DNA demethylase levels, promotes hypomethylation, increases the expression of tumor suppressor genes, inhibits leukaemia-initiating potential of AML cells, promotes differentiation of AML cells, and inhibits cancer progression in AML, via up-regulation of its target gene, 6/February/2019, 11.22 pm

Introduction to what they say: A study from the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), 69120 Heidelberg, Germany; Division of Stem […]